Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973747 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
NCT05973747: Completed Early Phase 1 study, sponsored by Stanford University.
NCT05973747 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 34 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973747, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Calcium is a life saving medicine in the care of parturients. It has many important uses including treatment of hypocalcemia, treatment of magnesium toxicity, prevention of hypocalcemia during blood transfusion (of citrate containing blood products), treatment of hyperkalemia, and others. Recent clinical trials also suggest that calcium given after cord clamping may decrease blood loss in patients undergoing cesarean delivery. 2 FDA approved forms of calcium can be given intravenously: calcium chloride and calcium gluconate. Over the last decade there have been times with drug shortages of either calcium chloride or calcium gluconate. So there have been and likely will continue to be times when one formulation or the other may not be adequately available. Despite the importance of calcium and the frequency in which it is used in parturients, there are no published studies in parturients to determine dose equivalence between calcium gluconate and calcium chloride. In this study the investigators will determine the population pharmacokinetics of calcium gluconate and calcium chloride in parturients and calculate the dose equivalent ratio the two drugs. This will help clinicians select appropriate doses of calcium and provide resilience to the drug supply chain in our era of frequent drug shortages.
Primary Outcome
Calculated via NONMEM
Interventions
- DRUG Calcium Gluconate
- DRUG Calcium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-08-19 |
| Est. Completion | 2023-12-15 |
| Phase | Early Phase 1 |
What the finished NCT05973747 record still lists
NCT05973747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 2 interventions - of which Calcium Gluconate is the first listed.
NCT05973747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05973747 about?
NCT05973747 is a clinical study titled "Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients". Calcium is a life saving medicine in the care of parturients. It has many important uses including treatment of hypocalcemia, treatment of magnesium toxicity, prevention of hypocalcemia during blood transfusion (of citrate containing blood products), treatment of hyperkalemia, and others. Recent cli...
What is the current status of trial NCT05973747?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2023-08-19. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05973747?
The interventions under investigation include: Calcium Gluconate (DRUG), Calcium chloride (DRUG).
Who is sponsoring clinical trial NCT05973747?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05973747's enrollment target sits among peer trials
34 748th of 2000 higher than 1,239 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI